Stryker Corporation $SYK Shares Purchased by CWS Financial Advisors LLC

CWS Financial Advisors LLC boosted its stake in shares of Stryker Corporation (NYSE:SYK) by 0.0% in the 1st quarter, Holdings Channel.com reports. The firm owned 256,669 shares of the medical technology company’s stock after buying an additional 88 shares during the quarter. Stryker makes up 30.2% of CWS Financial Advisors LLC’s holdings, making the stock its largest holding. CWS Financial Advisors LLC’s holdings in Stryker were worth $95,545,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in the stock. GAMMA Investing LLC raised its stake in shares of Stryker by 43,226.8% in the 1st quarter. GAMMA Investing LLC now owns 2,074,922 shares of the medical technology company’s stock valued at $772,390,000 after buying an additional 2,070,133 shares in the last quarter. Nuveen LLC acquired a new position in Stryker in the first quarter worth about $558,075,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Stryker in the fourth quarter worth about $154,140,000. Northern Trust Corp raised its position in Stryker by 13.2% in the fourth quarter. Northern Trust Corp now owns 3,606,237 shares of the medical technology company’s stock worth $1,298,426,000 after purchasing an additional 420,153 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in Stryker by 1.1% in the first quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock worth $12,306,572,000 after purchasing an additional 361,136 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

NYSE SYK opened at $381.91 on Tuesday. The stock has a fifty day moving average of $386.77 and a 200-day moving average of $379.38. The stock has a market capitalization of $146.01 billion, a P/E ratio of 50.58, a price-to-earnings-growth ratio of 2.78 and a beta of 0.91. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating the consensus estimate of $3.07 by $0.06. The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period last year, the firm earned $2.81 EPS. On average, equities research analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s payout ratio is currently 44.50%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 5.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

SYK has been the subject of a number of recent research reports. Wells Fargo & Company increased their target price on Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Roth Mkm increased their price objective on Stryker from $405.00 to $456.00 and gave the stock a “buy” rating in a research note on Friday, May 2nd. Truist Financial set a $415.00 price objective on Stryker and gave the stock a “hold” rating in a research note on Monday, August 4th. BTIG Research reiterated a “buy” rating on shares of Stryker in a research note on Monday, July 14th. Finally, Evercore ISI increased their target price on shares of Stryker from $390.00 to $415.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 8th. Four research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $430.10.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.